KCM
ABEO icon

Kennedy Capital Management’s Abeona Therapeutics ABEO Stock Holding History

Kennedy Capital Management’s Portfolio ABEO Stock Details ABEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.66M Buy
1,263,511
+213,416
+20% +$1.07M 0.12% 267
2025
Q4 		$5.53M Sell
1,050,095
-768
-0.1% -$3.87K 0.12% 278
2025
Q3 		$5.55M Buy
1,050,863
+378,860
+56% +$2.4M 0.12% 279
2025
Q2 		$3.82M Buy
672,003
+50,240
+8% +$286K 0.09% 335
2025
Q1 		$2.96M Buy
+621,763
New +$3.38M 0.07% 370

Other funds holding ABEO

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Kennedy Capital Management's ABEO Position: Q1 2026 in Review

Kennedy Capital Management increased its Abeona Therapeutics (ABEO) stake by 20% in Q1 2026, buying an estimated $1.07M and bringing the position to 1,263,511 shares worth $5.66M. The position accounts for 0.12% of the portfolio, ranked #267.

Kennedy Capital Management first reported a position in ABEO in Q1 2025 and has held it in 5 quarters since. 108 funds tracked by Wall St. Rank hold ABEO as of Q1 2026.

  • Kennedy Capital Management held 1,263,511 shares of Abeona Therapeutics worth $5.66M as of Q1 2026.
  • Kennedy Capital Management bought 213,416 Abeona Therapeutics shares in Q1 2026, an estimated $1.07M.
  • Abeona Therapeutics made up 0.12% of Kennedy Capital Management's portfolio in Q1 2026, its #267 holding.
  • Kennedy Capital Management first reported a position in Abeona Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • 108 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q1 2026.

Based on Kennedy Capital Management's 13F filing for Q1 2026, filed 13 May 2026.